Insider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Sells 4,646 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow sold 4,646 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. The trade was a 10.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Day One Biopharmaceuticals Stock Up 1.6 %

Day One Biopharmaceuticals stock opened at $12.43 on Friday. The company’s 50-day moving average price is $12.37 and its 200-day moving average price is $13.47. Day One Biopharmaceuticals, Inc. has a twelve month low of $11.13 and a twelve month high of $18.07. The company has a market cap of $1.25 billion, a PE ratio of -12.07 and a beta of -1.46.

Institutional Trading of Day One Biopharmaceuticals

Large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth about $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Day One Biopharmaceuticals by 15.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 75,579 shares of the company’s stock worth $958,000 after purchasing an additional 10,386 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth about $380,000. Stonepine Capital Management LLC boosted its stake in shares of Day One Biopharmaceuticals by 14.3% during the 4th quarter. Stonepine Capital Management LLC now owns 235,000 shares of the company’s stock worth $2,977,000 after purchasing an additional 29,325 shares during the period. Finally, Tema Etfs LLC purchased a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth about $1,087,000. 87.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on DAWN shares. The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Bank of America reduced their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and an average target price of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.